The process of CAR T therapy involves several steps. Initially, T-cells are extracted from the patient's blood. These cells are then genetically engineered in a lab to produce chimeric antigen receptors (CARs) on their surface. These CARs enable T-cells to recognize and bind to specific proteins on the surface of cancer cells. After expansion to create a sufficient quantity, the modified T-cells are infused back into the patient’s bloodstream, where they seek out and destroy cancer cells.
